Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

Figure 4

Response rates on various efficacy parameters. (A) and (B) ACR20, ACR50 and ACR70 response rates at week 24 (observed) and week 52 (NRI) for the 60-mg tabalumab group and the 60-mg/120-mg tabalumab group, respectively. (C) and (D) The EULAR28 (good + moderate) response rates for the 60-mg tabalumab and 60-mg/120-mg tabalumab groups, respectively, at week 24 (observed) and week 52 (LOCF). ACR, American College of Rheumatology Responder Index; EULAR28, European League against Rheumatism Responder Index based on 28 joints; LOCF, Last observation carried forward; n, Number of responders; N, Number of patients per treatment arm; NRI, Imputed as nonresponders; Wks, Weeks.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us